| Literature DB >> 34369416 |
Sebastien P F JanssensdeVarebeke1,2, Julie Moyaert3, Erik Fransen4,5, Britt Bulen1, Celine Neesen1, Katrien Devroye1, Raymond van de Berg6, Ronald J E Pennings7,8, Vedat Topsakal3, Olivier Vanderveken3, Guy Van Camp4,9, Vincent Van Rompaey2,3.
Abstract
INTRODUCTION: DFNA9 is characterized by adult-onset progressive sensorineural hearing loss (SNHL) and vestibular impairment. More than 15 years ago, genotype-phenotype correlation studies estimated the initial age of hearing deterioration in the fourth to fifth decade (ranging from 32 to 43 years). However, these analyses were based on relatively limited numbers of mainly symptomatic carriers using markedly different methodologies. The starting point for the hearing deterioration is more correctly determined with larger numbers of carriers and with a more clearly defined starting point of the hearing deterioration. AIM: The aim of this study was to determine milestone ages (start and maximal hearing deterioration, potential eligibility for hearing aids and cochlear implants based on pure-tone average [PTA]) in a large series of p.Pro51Ser COCH variant carriers. The degree of individual interaural asymmetry and the degree of variability (interquartile range) with which the hearing deterioration progresses across ages were also studied, and age-related typical audiograms (ARTA) were constructed.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34369416 PMCID: PMC8542086 DOI: 10.1097/AUD.0000000000001099
Source DB: PubMed Journal: Ear Hear ISSN: 0196-0202 Impact factor: 3.570
Demographics of study population, all carriers of the p.Pro51Ser COCH mutation (P51S) (n = 111)
| Age (Decade) | Age (Mean) | Age (Range) | Number (Ears) | Number Male (Ears) | Number Female (Ears) | SD |
|---|---|---|---|---|---|---|
|
| 22.4 | (18–25) | 10 | 2 | 8 | 2.55 |
|
| 35.19 | (30–39) | 32 | 18 | 14 | 3.10 |
|
| 45.44 | (40–49) | 42 | 26 | 16 | 2.61 |
|
| 54.96 | (50–59) | 52 | 16 | 36 | 2.70 |
|
| 64.54 | (60–69) | 58 | 34 | 24 | 2.12 |
|
| 75.07 | (70–80) | 28 | 12 | 16 | 3.18 |
Fig. 1.A, B, Hearing thresholds of 5 (10 ears) p.P51S variant carriers aged in the third decade in relation to the corresponding p50th, p95th, and p97.5th percentile values for presbyacusis, for male (A) and female carriers (B). Note that (A) only represents data from one subject. The upper and lower borders of the boxes represent 25th and 75th quartiles, respectively. The boxes contain 50% of the values and represent the IQR. The bold horizontal lines in the boxes are the medians (asterix [*]: the mean value of the hearing thresholds of corresponding decade is significantly greater than corresponding age-referenced limit [ISO 7029]). IQR, interquartile range.
Fig. 3.A, B, Hearing thresholds of 21 (42 ears) p.P51S variant carriers aged in the fifth decade in relation to the corresponding p50th, p95th, and p97.5th percentile values for presbyacusis, for male (A) and female carriers (B). The upper and lower borders of the boxes represent 25th and 75th quartiles, respectively. The boxes contain 50% of the values and represent the IQR. The bold horizontal lines in the boxes are the medians (asterix [*]: the mean value of the hearing thresholds of corresponding decade is significantly greater than corresponding age-referenced limit [ISO 7029]). IQR, interquartile range.
Age of onset of hearing loss according to age for male and female carriers of the P51S COCH mutation (n = 111)
| Frequency (kHz) | Male Carriers (n = 54) | Female Carriers (n = 57) |
|---|---|---|
|
| Fourth | Fourth |
|
| Fifth | Fifth |
|
| Fifth | Fifth |
|
| Sixth | Fifth |
|
| Fifth | Fifth |
|
| Fifth | Fifth |
|
| Fifth | Fourth |
|
| Fifth | Third |
|
| Fifth | Third |
|
| Fifth | Fifth |
|
| Fifth | Third |
|
| Fifth | Third |
PTA, pure-tone average.
Significance level of one-sample t test per frequency and PTAs of auditory data of male (A) and female (B) p.P51S carriers when compared with respective p95th percentile values (age-referenced ISO 7029 limits): (–: mµ = not greater than; +: mµ = greater than the p95th age-referenced value)
| (A) | ||||||||||||
| Male Carriers (n = 54) | 0.125 kHz | 0.250 kHz | 0.500 kHz | 1 kHz | 2 kHz | 3 kHz | 4 kHz | 6 kHz | 8 kHz | PTA 0.5–4 | PTA 4–8 | PTA 6–8 |
|
| – | – | – | – | – | – | – | – | – | – | – | – |
|
| + | – | – | – | – | – | – | – | – | – | – | – |
|
| + | + | + | – | + | + | + | + | + | + | + | + |
| Sixth decade | + | + | + | + | + | + | + | + | + | + | + | + |
| (B) | ||||||||||||
| Female Carriers (N = 57) | 0.125 kHz | 0.250 kHz | 0.500 kHz | 1 kHz | 2 kHz | 3 kHz | 4 kHz | 6 kHz | 8 kHz | PTA 0.5–4 | PTA 4–8 | PTA 6–8 |
|
| – | – | – | – | – | – | – | + | + | – | + | + |
|
| + | – | – | – | – | – | + | + | + | – | + | + |
| Fifth decadE | + | + | + | + | + | + | + | + | + | + | + | + |
|
| + | + | + | + | + | + | + | + | + | + | + | + |
PTA, pure-tone average.
Fig. 4.Frequency-specific progression of hearing thresholds in 54 male p.P51S variant carriers in function of their age (108 ears). Note that hearing loss starts earlier with higher frequencies, whereas there is a constant offset hearing threshold at lower frequencies which lies within range of normative values for 0.125 to 4 kHz.
Fig. 5.Frequency-specific progression of hearing thresholds in 57 female p.P51S variant carriers in function of their age (114 ears). Note that hearing loss starts earlier with higher frequencies, whereas there is a constant offset hearing threshold at lower frequencies which lies within range of normative values for 0.125 to 3 kHz.
Summary of all estimated ages at which the hearing deterioration starts, reaches 33.33% (=40 dB HL), 50%, 58.33% (=70 dB HL), and maximal progression, as well as estimates of the ATD, with 95% confidence intervals in 54 male P51S carriers (all estimated were computed based on nonlinear drc-regression models)
| Male Carriers (n = 54) (kHz) | Onset (Decade) | Age of Onset (years)+ 95% CI | ED 33.33 | ED 50 | ED 58.33 | ED max | Slope |
|---|---|---|---|---|---|---|---|
|
| Fifth | 44.983 (38.130; 51.837) | 52.953 (48.011; 57.896) | 57.158 (48.196; 65.621) | 59.512 (48.695; 70.827) | 87.583 (19.730; 155.436) | 3.285 (1.178; 5.410) |
|
| Fifth | 44.660 (40.400; 48.921) | 54.197 (47.360; 61.014) | 60.163 (48.476; 71.851) | 63.667 (48.682; 78.652) | 111.758 (34.405; 189.111) | 2.095 (1.708; 3.502) |
|
| Fifth | 44.620 (36.383; 52.857) | 53.417 (46.209; 60.626) | 58.711 (46.524; 70.898) | 61.657 (45.500; 77.815) | 97.167 (–1.923; 196.257) | 2.729 (1.845; 3.609) |
|
| Sixth | 46.455 (35.046; 57.863) | 51.923 (43.737; 60.109) | 57.523 (49.299; 65.757) | 60.184 (50.505; 69.863) | 82.360 (32.370; 132.349) | 3.180 (2.229 – 4.136) |
|
| Fifth | 45.596 (29.382; 61.811) | 51.561 (37.244; 65.878) | 57.566 (37.581; 77.551) | 60.740 (35.080; 86.399) | 95.169 (–61.108; 251.446) | 2.778 (2.019; 3.540) |
|
| Fifth | 41.929 (18.989; 64.869) | 46.463 (28.559; 64.367) | 53.083 (37.200; 68.967) | 56.382 (38.709; 74.054) | 87.570 (–9.634; 184.774) | 2.609 (2.190; 3.029) |
|
| Fifth | 45.672 (43.074; 48.271) | 47.287 (44.321; 50.253) | 52.099 (47.196; 57.001) | 54.916 (48.565; 61.266) | 93.045 (59.344; 126.746) | 2.112 (1.534; 2.690) |
|
| Fifth | 48.552 (44.006; 53.098) | 48.217 (43.809; 52.624) | 53.997 (46.525; 61.469) | 57.402 (47.681; 67.123) | 105.282 (49.674; 160.890) | 1.991 (1.497; 2.486) |
|
| Fifth | 48.595 (38.988; 58.202) | 46.618 (36.412; 56.824) | 51.972 (41.650; 62.295) | 54.769 (42.369; 67.170) | 84.272 (7.111; 161.433) | 3.324 (2.460; 4.188) |
|
| Fifth | 45.846 (37.263; 54.429) | 52.073 (41.904; 62.242) | 58.279 (41.020; 75.539) | 61.790 (38.764; 84.834) | 107.005(–48.720; 262.730) | 2.672 (1.994; 3.350) |
|
| Fifth | 47.721 (44.182; 51.261) | 47.697 (44.164; 51.229) | 52.851 (47.023; 58.680) | 55.855 (48.220; 63.490) | 96.439 (51.646; 141.241) | 2.159 (1.611; 2.707) |
|
| Fifth | 49.423 (44.293; 54.554) | 48.253 (43.662; 52.843) | 54.020 (46.092; 61.948) | 57.409 (46.975; 67.843) | 104.760(42.439; 167.081) | 2.003 (1.534; 2.472) |
ED or effective dose refers to the sigmoid-shaped dose-response relationship between the hearing threshold (dependent variable) with age (independent variable), which is expressed as the percentage by which the hearing theshold progresses with increasing age from the start to end. For example: ED50 refers to the value of the hearing threshold at half-way progression, ED100 refers to the end of the progression.
Estimated age at which the hearing deterioration has reached 33.33 % (effective dose) of its progression, which corresponds to 40 dB HL
Estimated age at which the hearing deterioration has reached 50% (effective dose) of its progression
Estimated age at which the hearing deterioration has reached 58.33% (effective dose) of its progression, corresponding to 70 dB HL.
Estimated age at which the hearing deterioration has reached its maximal progression
Slope is a measure of ATD in dB/y.
ATD, annual threshold deterioration; CI, confidence intervals; PTA, pure-tone average.
Summary of all estimated ages at which the hearing deterioration starts, reaches 33.33% (=40 dB HL), 50%, 58.33% (=70 dB HL) and maximal progression, as well as estimates of the ATD, with 95% confidence intervals in 57 female P51S carriers (all estimated were computed based on nonlinear drc-regression models)
| Female Carriers (n = 57) (kHz) | Onset (Decade) | Age of Onset (years) + 95% CI | ED 33.33 | ED 50 | ED 58.33 | EDmax | Slope |
|---|---|---|---|---|---|---|---|
|
| Fifth | 42.860 (30.798; 54.922) | 53.891 (49.694; 58.088) | 57.988 (54.923; 61.053) | 59.818 (56.606; 63.031) | 72.843 (56.498; 89.188) | 2.396 (0.345; 5.574) |
|
| Fifth | 38.622 (25.562; 51.681) | 50.711 (44.805; 56.618) | 55.765 (52.032; 59.497) | 57.955 (54.420; 61.491) | 71.938(55.475; 88.401) | 3.513 (2.195; 4.831) |
|
| Fifth | 41.800 (29.016; 54.585) | 52.149 (46.451; 57.846) | 57.304 (51.210; 63.397) | 59.830 (52.287; 67.372) | 82.562(38.090; 127.034) | 3.433 (2.467; 4.433) |
|
| Fifth | 42.132 (31.949; 52.316) | 51.262 (46.823; 55.702) | 55.815 (52.497; 59.133) | 57.897 (54.298; 61.500) | 73.635 (53.324; 93.946) | 4.557 (3.135; 5.978) |
|
| Fifth | 41.663 (32.868; 50.458) | 49.371 (45.031; 53.711) | 54.164 (50.129; 58.200) | 56.514 (51.656; 61.372) | 77.666 (46.581; 108.751) | 3.583 (2.629; 4.536) |
|
| Fourth | 34.443 (21.188; 47.698) | 46.170 (40.290; 52.050) | 51.851 (46.713; 56.988) | 54.620 (48.644; 60.596) | 79.339 (40.599; 118.059) | 2.644 (1.921; 3.367) |
|
| Fourth | 37.694 (30.431; 44.957) | 46.561 (40.722; 52.400) | 53.008 (42.728; 63.287) | 56.754 (42.385; 71.123) | 108.793 (–16.184; 233.771) | 1.994 (1.573; 2.414) |
|
| Third | 34.917 (–17.566; 87.400) | 44.525 (25.778; 63.273) | 50.172 (25.495; 74.849) | 53.218 (18.276; 88.160) | 88.167 (–261.760; 438.094) | 2.319 (1.732; 2.906) |
|
| Third | 27.851 (14.123; 41.579) | 41.45 (32.57; 50.34) | 48.52 (43.04; 54.00) | 51.54 (47.30; 55.78) | 66.87 (53.21; 80.53) | 2.319 (1.732; 2.919) |
|
| Fifth | 40.849 (31.235; 50.463) | 49.432 (44.532; 54.332) | 54.682 (50.180; 59.185) | 57.213 (51.865; 62.562) | 79.121 (46.596; 111.647) | 3.392 (2.546; 4.237) |
|
| Third | 35.603 (15.446 55.761) | 45.513 (36.447; 54.579) | 51.469 (38.755; 64.183) | 54.714 (37.147; 72.281) | 92.972 (–64.442; 250.369) | 1.899 (1.516; 2.282) |
|
| Third | 31.795 (–14.002; 77.591) | 43.495 (25.713; 61.277) | 49.398 (38.012; 60.784) | 52.173 (39.927; 64.420) | 74.546 (–37.884; 186.977) | 2.799 (1.989; 3.609) |
ED or effective dose refers to the sigmoid-shaped dose-response relationship between the hearing threshold (dependent variable) with age (independent variable), which is expressed as the percentage by which the hearing theshold progresses with increasing age from the start to end. For example: ED50 refers to the value of the hearing threshold at half-way progression, ED100 refers to the end of the progression.
Estimated age at which the hearing deterioration has reached 33.33 % (effective dose) of its progression, which corresponds to 40 dB HL.
Estimated age at which the hearing deterioration has reached 50% (effective dose) of its progression.
Estimated age at which the hearing deterioration has reached 58.33 % (effective dose) of its progression, corresponding to 70 dB HL.
Estimated age at which the hearing deterioration has reached its maximal progression.
Slope is a measure of ATD in dB/y.
ATD, annual threshold deterioration; CI, confidence intervals; PTA, pure-tone average.
Fig. 6.Interaural hearing threshold difference (dB HL) at all frequencies (0.125 to 8 kHz) in 21 P51S carriers (42 ears) (male and female) aged from 18 to 39 years. Note the higher level of threshold difference at highest frequencies (dotted line = 10 dB interaural difference).
The IQR of hearing thresholds from 111 P51S carriers separated into three different age groups
| Frequency (kHz) | Age Group 1 (18–39 years) n = 21 | Age Group 2 (40–59 years) n = 43 | Age Group 3 (60–80 years) n = 43 |
|---|---|---|---|
|
| 10 | 35 | 58.75 |
|
| 5 | 35 | 33.75 |
|
| 8.75 | 40 | 38.75 |
|
| 5 | 40 | 35 |
|
| 5 | 40 | 35 |
|
| 15 | 40 | 33.75 |
|
| 15 | 40 | 25 |
|
| 13.75 | 33.75 | 25 |
|
| 15 | 30 | 20 |
|
| 10.28 | 37.08 | 33.89 |
The mean IQR scores are highest in the age group 40–59 years and are the lowest in the age group 18–39.
IQR, interquartile range.
Correlation coefficients between individual right and left hearing thresholds in 111 P51S carriers, separated into three age groups, showing higher coefficient values being consistent with less interaural asymmetry
| Age Group | Frequency | Spearman |
|---|---|---|
|
|
| 0.723 |
|
| 0.637 | |
|
| 0.451 | |
|
| 0.521 | |
|
| 0.082 | |
|
| 0.522 | |
|
| 0.316 | |
|
| 0.415 | |
|
| 0.271 | |
|
|
| 0.715 |
|
| 0.703 | |
|
| 0.752 | |
|
| 0.665 | |
|
| 0.598 | |
|
| 0.543 | |
|
| 0.544 | |
|
| 0.589 | |
|
| 0.544 | |
|
|
| 0.653 |
|
| 0.591 | |
|
| 0.564 | |
|
| 0.522 | |
|
| 0.549 | |
|
| 0.475 | |
|
| 0.511 | |
|
| 0.741 | |
|
| 0.812 |
Note the same pattern compared with Figures 6–8, with lower degrees of interaural differences at lower frequencies in age group 18–39 and at higher frequencies in age group 60–80.
Fig. 8.Interaural hearing threshold difference (dB HL) at all frequencies (0.125 to 8 kHz) in 47 P51S carriers (94 ears) (male and female) aged from 60 to 80 years. Note the higher level of threshold differences at lower frequencies (dotted line = 10 dB interaural difference).
Fig. 9.ARTA based on observed data from 54 male (A) and 57 female (B) p.P51S carriers (observed ARTA).
Fig. 10.Predicted ARTA derived from nonlinear dose-response regression model for male (A) and female (B) p.P51S carriers with corresponding 95% confidence intervals.